VOLUME 64   2003   SUPPLEMENT 17

ARTICLES

3 Efficacy and Effectiveness of First- and Second-Generation Antipsychotics in Schizophrenia. Ari B. Jaffe and Jerome Levine
[Abstract] [PDF]

7 Similarities and Differences Among Antipsychotics. Carol A. Tamminga
[Abstract] [PDF]

11 Impact of Formularies on Clinical Innovation. Frederick K. Goodwin
[Abstract] [PDF]

15 The Economic and Human Impact of New Drugs. Frank R. Lichtenberg
[Abstract] [PDF]

19 Unintended Outcomes of Medicaid Drug Cost-Containment Policies on the Chronically Mentally Ill. Stephen Soumerai
[Abstract] [PDF]

23 Limiting Access to Psychiatric Services Can Increase Total Health Care Costs. Susan D. Horn
[Abstract] [PDF]

29 Weighing the Evidence: Trends in Managed Care Formulary Decision Making. Gregory de Lissovoy
[Abstract] [PDF]

33 Commentary: Purchasing Community Perspective. Marsha C. Moore
[PDF]

35 Commentary: Health Care Organization Perspective. William Goldman
[PDF]

37 Commentary: Government Perspective. Joseph J. Parks
[PDF]

39 Commentary: Advocacy Perspective. Michael J. Fitzpatrick
[PDF]